alexa Adoptive Cellular Immunotherapy For Viral Diseases Post-transplant
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

12th Global Nephrologists Annual Meeting
June 26-28, 2017 London, UK

Petra Reinke
Charite - Universitatsmedizin Berlin, Germany
Keynote: J Nephrol Ther
DOI: 10.4172/2161-0959-C1-038
The intensity and long-term requirement for immunosuppression to prevent allograft rejection pre-disposes solid organ transplant (SOT) recipients to a wide range of viral complications, particularly within the first year of transplant. The agents administered post-transplant to prevent organ rejection compromise the host immune system leaving patients vulnerable to an array of latent and lytic viruses including cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), human herpes virus 6 (HHV6) and BK virus. Many of the viruses account for a spectrum of clinical diseases in SOT recipients including allograft dysfunction. As a result, viral infection or reactivation is a frequent cause of morbidity and mortality in immunocompromised SOT recipients. Adoptive T-cell therapy using virus-specific T-cells (VST) has emerged as an effective treatment option in viral diseases after SOT and hematopoietic stem cell transplantation (HSCT). Despite vast success of anti-viral T-cell therapeutic approaches following HSCT, T-cell engraftment and longevity of the efficacy is incidentally limited in chronically immunocompromised SOT patients due to insufficient persistence of T-cells after infusion and reduced proliferation. Successful anti-viral T-cell immunotherapy depends on a range of cell and patient-dependent factors. In my presentation, I will describe challenges and limitations for VST production in the SOT setting, the innovations that allowed the production of anti-viral T-cell products, including an optimized T-cell subset composition of the VST infused, genetically modified VST, third-party VST and multi-virus-specific T-cell products, and I will discuss the potential and first clinical data for this approach.

Petra Reinke is Nephrologist and Clinical Scientist. Her scientific topics are: Transplantation medicine, development of new diagnostic and therapeutic approaches in transplantation. She is Project Coordinator for the EU founded FP7 consortium “BIO-DrIM”, was Steering Committee Member/Work-package Leader of the EU founded FP7 consortium “ONE- Study”, Steering Committee Member/Work-package Leader of the EU founded FP6 consortium “RISET”, Co-PI for a project founded by the Immune Tolerance Network, Co-Investigator ROTF grant. She is Head of the “Kidney Transplant Outpatient Clinic”; Head of research area “Immune System”, Head of the GMP-Facility, Steering Committee Member of the Berlin-Brandenburg Center for Regenerative Therapies, of the DFG-sponsored Berlin-Brandenburg School for Regenerative Therapies, of the Berlin Institute of Health (BIH) Stem Cell Center. She published more than 300 articles.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version